期刊
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
卷 20, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12958-022-00892-8
关键词
Premature ovarian insufficiency; Therapeutic options; Stem cell therapy; In vitro activation; Mitochondrial activation technique; Platelet rich plasma
资金
- Science and Technology Bureau of Quanzhou [2020CT003]
Primary ovarian insufficiency is a rare gynecological condition that results in menstrual disturbances, infertility, and other health problems. The development of new therapeutic approaches is underway, but they are still in the experimental stage and require precise design components for conversion into clinical treatments. Each medical practitioner has the responsibility to select suitable therapies for individual patients.
Primary ovarian insufficiency (POI) is a rare gynecological condition. This disease causes menstrual disturbances, infertility, and various health problems. Historically, hormone replacement therapy is the first-line treatment for this disorder. Women diagnosed with POI are left with limited therapeutic options. In order to remedy this situation, a new generation of therapeutic approaches, such as in vitro activation, mitochondrial activation technique, stem cell and exosomes therapy, biomaterials strategies, and platelet-rich plasma intra-ovarian infusion, is being developed. However, these emerging therapies are yet in the experimental stage and require precise design components to accelerate their conversion into clinical treatments. Thus, each medical practitioner bears responsibility for selecting suitable therapies for individual patients. In this article, we provide a timely analysis of the therapeutic strategies that are available for POI patients and discuss the prospects of POI therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据